> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CGMP Violations at Verde Cosmetic Labs
- URL: https://www.fdaweb.com/cgmp-violations-at-verde-cosmetic-labs/
- Published: 2022-08-16T12:00:00.000Z
- Updated: 2026-09-14T17:55:59.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152514

A 9/27-10/15/21 FDA inspection at the Verde Cosmetic Labs drug manufacturing facility in Northridge, CA, found significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals. A just-released 3/30 [Warning Letter](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/verde-cosmetic-labs-llc-622534-03302022?ref=fdaweb.com) says specific violations were:

- failure of the firm’s quality control unit to exercise its responsibility to ensure drug products manufactured comply with CGMP and meet established specifications for identity, strength, quality, and purity;
- failing to establish adequate written procedures for production and process control designed to assure that the drug products manufactured have the identity, strength, quality, and purity they purport or are represented to possess;
- failing to establish and follow adequate written procedures for cleaning and maintaining equipment; and
- failing to document at the time of performance required laboratory control mechanisms and to record and justify any deviations from required laboratory control mechanisms.

The letter says the firm’s quality systems are inadequate and the agency recommends engaging a qualified consultant to assist Verde in meeting CGMP requirements.

Verde was told to respond with a list of specific steps it has taken to address the violations and prevent their recurrence, with a schedule for completing the corrections.